Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28119029 | 1.00 | EPAS1 (0.33) | EPAS1ALDH1A1HTR6 | |
| SCHEMBL8193143 | 0.98 | EPAS1 (0.32) | EPAS1ALDH1A1 | |
| Piperazine SCHEMBL9068838 | 0.98 | EPAS1 (0.32) | EPAS1ALDH1A1 | |
| SCHEMBL27492799 | 0.98 | EPAS1 (0.34) | EPAS1ALDH1A1HTR6 | |
| SCHEMBL23373293 | 0.93 | HTR2C (0.32) | EPAS1 | |
| SCHEMBL8873462 | 0.88 | EPAS1 (0.36) | EPAS1ALDH1A1 | |
| SCHEMBL17335 | 0.87 | — | — | |
| SCHEMBL16908175 | 0.87 | — | — | |
| SCHEMBL17336 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL29197502 | 0.85 | L3MBTL1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4705788-A | Novel antibacterial 7-amino-1(substituted cyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | claimed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-4705788-A | Novel antibacterial 7-amino-1(substituted cyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| EP-0225552-A2 | Pure enantiomeric 1,8-bridged-4-quinolo-3-carboxylic acids, process for their preparation and medicaments containing them, and their use in the preparation of medicaments | BAYER AG (DE) | 1987-06-16 | — | — | EP | disclosed |
| EP-0224176-A1 | Process for preparing oligomers and telechelics with carboxy-piperazine units, and oligomers and telechelics of poly(carboxypiperazine) | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
| CN-86104256-A | 1, the preparation method of 8-bridging 4-quinolone-3-carboxylic-acid | — | 1987-03-18 | — | — | CN | disclosed |
| EP-0206076-A2 | 1,8-Bridged 4-quinolone-3-carboxylic acids, process for their preparation as well as medicaments containing them, and their use for the preparation of medicaments | BAYER AG (DE) | 1986-12-30 | — | — | EP | disclosed |
| EP-0198192-A1 | 7-Amino-1-(subst.cyclopropyl)-1,4 -dihydro-4-oxo-quinoline carboxylic acids, method for their preparation, and antibacterial agents containing them | BAYER AG (DE) | 1986-10-22 | — | — | EP | disclosed |
| US-4599334-A | 7-(3-aryl-1-piperazinyl)- and 7-(3-cyclohexyl-1-piperazinyl)-3-quinolonecarboxylic acid antibacterials | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-08 | — | — | US | disclosed |
| EP-0169993-A2 | 7-(3-Aryl-1-piperazinyl) and 7-(3-cyclohexyl-1-piperazinyl) 3-quinoline carboxylic acids | BAYER AG (DE) | 1986-02-05 | — | — | EP | disclosed |
| EP-0167763-A1 | 7-Amino-1-cyclopropyl-6,8-dihalo-1,4-dihydro-4-oxo-3-quinoline-carboxylic acids, process for their preparation and bactericidal agents containing them | BAYER AG (DE) | 1986-01-15 | — | — | EP | disclosed |
| EP-0164619-A1 | 2,4,5-Trihalo or 2,3,4,5-tetrahalo benzene derivatives and process for producing them | BAYER AG (DE) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | EPAS1 2971/4885ALDH1A1 3960/4885HTR6 3358/4885 |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | EPAS1 3558/4885ALDH1A1 4019/4885HTR6 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.